Progression-Free Survival 2

Biomarker

Also known as: PFS2

Related News

Zanubrutinib Shows Sustained PFS Benefit at 6 Years in SEQUOIA CLL Trial

Jul 14, 2026

Six-year SEQUOIA trial data show zanubrutinib sustains a progression-free survival advantage (74% vs 32%) over bendamustine-rituximab in CLL without del(17p). Benefit extends to high-risk del(17p) patients.

Lilly's Retevmo Shows Significant Event-Free Survival Benefit in Early-Stage Lung Cancer Trial

Feb 16, 2026

Eli Lilly announced positive Phase 3 LIBRETTO-432 trial results showing Retevmo (selpercatinib) significantly improved event-free survival in patients with early-stage RET fusion-positive non-small cell lung cancer as adjuvant therapy.